You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolazamide
Accession NumberDB00839  (APRD01267)
TypeSmall Molecule
GroupsApproved
DescriptionA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. [PubChem]
Structure
Thumb
Synonyms
1-(hexahydro-1-Azepinyl)-3-P-tolylsulfonylurea
1-(hexahydro-1H-Azepin-1-yl)-3-(P-tolylsulfonyl)urea
4-(P-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide
BRN 1323565
CCRIS 591
Diabewas
EINECS 214-588-3
N-(P-Toluenesulfonyl)-n'-hexamethyleniminourea
N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide
Norglycin
Tolazamid
Tolazamida
Tolazamide
Tolazamidum
Tolinase
U 17835
U-17835
External Identifiers
  • U 17835
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tolazamidetablet250 mg/1oralMylan Pharmaceuticals Inc.2013-01-18Not applicableUs
Tolazamidetablet500 mg/1oralMylan Pharmaceuticals Inc.2013-01-18Not applicableUs
Tolazamidetablet250 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DesumideHua Shin
EsulinChung Mei
NorglycinPfizer
TolanaseUpjohn
TolinaseNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9LT1BRO48Q
CAS number1156-19-0
WeightAverage: 311.4
Monoisotopic: 311.130362243
Chemical FormulaC14H21N3O3S
InChI KeyInChIKey=OUDSBRTVNLOZBN-UHFFFAOYSA-N
InChI
InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
IUPAC Name
1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea
SMILES
CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Tosyl compound
  • Benzenesulfonamide
  • Toluene
  • Sulfonylurea
  • Azepane
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Semicarbazide
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.
PharmacodynamicsTolazamide is an oral blood glucose lowering drug of the sulfonylurea class. Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. Some patients who are initially responsive to oral hypoglycemic drugs, including tolazamide, may become unresponsive or poorly responsive over time. Alternatively, tolazamide may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose lowering actions, tolazamide produces a mild diuresis by enhancement of renal free water clearance.
Mechanism of actionSulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
Related Articles
AbsorptionRapidly and well absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%.

Route of eliminationTolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0% to 70%. They are excreted principally in the urine.
Half lifeThe average biological half-life of the drug is 7 hours.
ClearanceNot Available
ToxicityOverdosage of sulfonylureas can produce hypoglycemia. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9749
Blood Brain Barrier+0.8467
Caco-2 permeable-0.6444
P-glycoprotein substrateSubstrate0.7039
P-glycoprotein inhibitor INon-inhibitor0.8125
P-glycoprotein inhibitor IINon-inhibitor0.9824
Renal organic cation transporterNon-inhibitor0.8497
CYP450 2C9 substrateSubstrate0.622
CYP450 2D6 substrateNon-substrate0.8816
CYP450 3A4 substrateNon-substrate0.7268
CYP450 1A2 substrateNon-inhibitor0.9274
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9268
CYP450 2C19 inhibitorNon-inhibitor0.9104
CYP450 3A4 inhibitorNon-inhibitor0.84
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.962
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8461
BiodegradationNot ready biodegradable0.7221
Rat acute toxicity1.8259 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8064
hERG inhibition (predictor II)Non-inhibitor0.8047
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Interpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Superpharm corp
  • Usl pharma inc
  • Watson laboratories inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
Tabletoral250 mg/1
Tabletoral500 mg/1
Prices
Unit descriptionCostUnit
Tolazamide 500 mg tablet1.41USD tablet
Tolinase 250 mg tablet1.23USD tablet
Tolazamide 250 mg tablet0.79USD tablet
Tolazamide 100 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170-173 °CPhysProp
water solubility65.4 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.69SANGSTER (1993)
logS-3.68ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.308 mg/mLALOGPS
logP1.4ALOGPS
logP1.91ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)4.07ChemAxon
pKa (Strongest Basic)1.61ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.51 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity81.34 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-06r6-9500000000-41e71d724a7515763bb7View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA10BB05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Tolazamide.
AcarboseAcarbose may increase the hypoglycemic activities of Tolazamide.
AcebutololAcebutolol may increase the hypoglycemic activities of Tolazamide.
AcenocoumarolTolazamide may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Tolazamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Tolazamide.
AicarAicar may increase the hypoglycemic activities of Tolazamide.
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Tolazamide.
AlogliptinAlogliptin may increase the hypoglycemic activities of Tolazamide.
AlprenololAlprenolol may increase the hypoglycemic activities of Tolazamide.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Tolazamide.
AmoxapineAmoxapine may increase the hypoglycemic activities of Tolazamide.
AripiprazoleThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.
ArotinololArotinolol may increase the hypoglycemic activities of Tolazamide.
Arsenic trioxideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Atazanavir.
AtenololAtenolol may increase the hypoglycemic activities of Tolazamide.
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Tolazamide.
BefunololBefunolol may increase the hypoglycemic activities of Tolazamide.
BendroflumethiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Tolazamide.
BetamethasoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Betamethasone.
BetaxololBetaxolol may increase the hypoglycemic activities of Tolazamide.
BevantololBevantolol may increase the hypoglycemic activities of Tolazamide.
BezafibrateBezafibrate may increase the hypoglycemic activities of Tolazamide.
BisoprololBisoprolol may increase the hypoglycemic activities of Tolazamide.
BopindololBopindolol may increase the hypoglycemic activities of Tolazamide.
BrexpiprazoleThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Brexpiprazole.
BuforminBuformin may increase the hypoglycemic activities of Tolazamide.
BufuralolBufuralol may increase the hypoglycemic activities of Tolazamide.
BumetanideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bumetanide.
BupranololBupranolol may increase the hypoglycemic activities of Tolazamide.
BuserelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Buserelin.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Tolazamide.
CarbocisteineThe risk or severity of adverse effects can be increased when Tolazamide is combined with Carbocisteine.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Tolazamide.
CarteololCarteolol may increase the hypoglycemic activities of Tolazamide.
CarvedilolCarvedilol may increase the hypoglycemic activities of Tolazamide.
CastanospermineCastanospermine may increase the hypoglycemic activities of Tolazamide.
CeliprololCeliprolol may increase the hypoglycemic activities of Tolazamide.
CeritinibThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ceritinib.
ChloramphenicolThe metabolism of Tolazamide can be decreased when combined with Chloramphenicol.
ChlorothiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorothiazide.
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Tolazamide.
ChlorthalidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorthalidone.
CiglitazoneCiglitazone may increase the hypoglycemic activities of Tolazamide.
CimetidineThe serum concentration of Tolazamide can be increased when it is combined with Cimetidine.
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Tolazamide.
CitalopramCitalopram may increase the hypoglycemic activities of Tolazamide.
ClofibrateClofibrate may increase the hypoglycemic activities of Tolazamide.
ClomipramineClomipramine may increase the hypoglycemic activities of Tolazamide.
ClozapineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Clozapine.
CorticotropinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dabrafenib.
DanazolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Danazol.
DapoxetineDapoxetine may increase the hypoglycemic activities of Tolazamide.
DarunavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dexamethasone.
DiazoxideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Diazoxide.
DicoumarolTolazamide may increase the anticoagulant activities of Dicoumarol.
DienogestThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dienogest.
DiflunisalDiflunisal may increase the hypoglycemic activities of Tolazamide.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Tolazamide.
DisopyramideTolazamide may increase the hypoglycemic activities of Disopyramide.
DrospirenoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Drospirenone.
DulaglutideDulaglutide may increase the hypoglycemic activities of Tolazamide.
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Tolazamide.
EpinephrineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Epinephrine.
EscitalopramEscitalopram may increase the hypoglycemic activities of Tolazamide.
EsmololEsmolol may increase the hypoglycemic activities of Tolazamide.
EstradiolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Tolazamide is combined with Ethanol.
Ethinyl EstradiolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethinyl Estradiol.
Ethyl biscoumacetateTolazamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethynodiol diacetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethynodiol diacetate.
EtofibrateEtofibrate may increase the hypoglycemic activities of Tolazamide.
EtonogestrelThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Tolazamide.
EverolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Everolimus.
ExenatideExenatide may increase the hypoglycemic activities of Tolazamide.
FenfluramineFenfluramine may increase the hypoglycemic activities of Tolazamide.
FenofibrateFenofibrate may increase the hypoglycemic activities of Tolazamide.
FluconazoleThe serum concentration of Tolazamide can be increased when it is combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Fludrocortisone.
FluoxetineFluoxetine may increase the hypoglycemic activities of Tolazamide.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Tolazamide.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Tolazamide.
FosamprenavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Fosamprenavir.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Tolazamide.
FurosemideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Furosemide.
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Tolazamide.
GlibornurideGlibornuride may increase the hypoglycemic activities of Tolazamide.
GliclazideTolazamide may increase the hypoglycemic activities of Gliclazide.
GlimepirideGlimepiride may increase the hypoglycemic activities of Tolazamide.
GlipizideTolazamide may increase the hypoglycemic activities of Glipizide.
GliquidoneGliquidone may increase the hypoglycemic activities of Tolazamide.
GlyburideTolazamide may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.
HistrelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Tolazamide.
HydrochlorothiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Iloperidone.
IndalpineIndalpine may increase the hypoglycemic activities of Tolazamide.
IndapamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Indapamide.
IndenololIndenolol may increase the hypoglycemic activities of Tolazamide.
IndinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Indinavir.
Insulin AspartTolazamide may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirTolazamide may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Tolazamide.
Insulin GlulisineTolazamide may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanTolazamide may increase the hypoglycemic activities of Insulin Human.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Tolazamide.
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Tolazamide.
IproclozideIproclozide may increase the hypoglycemic activities of Tolazamide.
IproniazidIproniazid may increase the hypoglycemic activities of Tolazamide.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Tolazamide.
LabetalolLabetalol may increase the hypoglycemic activities of Tolazamide.
LanreotideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lanreotide.
LanreotideTolazamide may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.
LevobunololLevobunolol may increase the hypoglycemic activities of Tolazamide.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Tolazamide.
LevonorgestrelThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Levonorgestrel.
LinagliptinLinagliptin may increase the hypoglycemic activities of Tolazamide.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Tolazamide.
LiraglutideLiraglutide may increase the hypoglycemic activities of Tolazamide.
LopinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lopinavir.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Tolazamide.
LurasidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone.
MebanazineMebanazine may increase the hypoglycemic activities of Tolazamide.
MecaserminTolazamide may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Medroxyprogesterone acetate.
Megestrol acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Megestrol acetate.
MesalazineMesalazine may increase the hypoglycemic activities of Tolazamide.
MestranolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Mestranol.
MetforminMetformin may increase the hypoglycemic activities of Tolazamide.
MethotrimeprazineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.
Methylene blueMethylene blue may increase the hypoglycemic activities of Tolazamide.
MethylprednisoloneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methylprednisolone.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Tolazamide.
MetipranololMetipranolol may increase the hypoglycemic activities of Tolazamide.
MetolazoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone.
MetoprololMetoprolol may increase the hypoglycemic activities of Tolazamide.
MetreleptinMetreleptin may increase the hypoglycemic activities of Tolazamide.
MiconazoleMiconazole may increase the hypoglycemic activities of Tolazamide.
MifepristoneTolazamide may increase the hypoglycemic activities of Mifepristone.
MiglitolMiglitol may increase the hypoglycemic activities of Tolazamide.
MiglustatMiglustat may increase the hypoglycemic activities of Tolazamide.
MilnacipranMilnacipran may increase the hypoglycemic activities of Tolazamide.
MinaprineMinaprine may increase the hypoglycemic activities of Tolazamide.
MitiglinideMitiglinide may increase the hypoglycemic activities of Tolazamide.
MoclobemideMoclobemide may increase the hypoglycemic activities of Tolazamide.
NadololNadolol may increase the hypoglycemic activities of Tolazamide.
NateglinideNateglinide may increase the hypoglycemic activities of Tolazamide.
NelfinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Tolazamide.
NilotinibThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Norgestimate.
OctamoxinOctamoxin may increase the hypoglycemic activities of Tolazamide.
OctreotideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Octreotide.
OctreotideTolazamide may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Tolazamide.
OxandroloneOxandrolone may increase the hypoglycemic activities of Tolazamide.
OxprenololOxprenolol may increase the hypoglycemic activities of Tolazamide.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Tolazamide.
PaliperidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone.
PargylinePargyline may increase the hypoglycemic activities of Tolazamide.
ParoxetineParoxetine may increase the hypoglycemic activities of Tolazamide.
PasireotideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Pasireotide.
PasireotideTolazamide may increase the hypoglycemic activities of Pasireotide.
PegvisomantPegvisomant may increase the hypoglycemic activities of Tolazamide.
PenbutololPenbutolol may increase the hypoglycemic activities of Tolazamide.
PentamidineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Pentamidine.
PentamidineTolazamide may increase the hypoglycemic activities of Pentamidine.
PhenelzinePhenelzine may increase the hypoglycemic activities of Tolazamide.
PhenforminPhenformin may increase the hypoglycemic activities of Tolazamide.
PhenindioneTolazamide may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the hypoglycemic activities of Tolazamide.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Tolazamide.
PhenprocoumonTolazamide may increase the anticoagulant activities of Phenprocoumon.
PindololPindolol may increase the hypoglycemic activities of Tolazamide.
PioglitazonePioglitazone may increase the hypoglycemic activities of Tolazamide.
PiperazineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Pipotiazine.
PirlindolePirlindole may increase the hypoglycemic activities of Tolazamide.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Tolazamide.
PolythiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Polythiazide.
PractololPractolol may increase the hypoglycemic activities of Tolazamide.
PramlintidePramlintide may increase the hypoglycemic activities of Tolazamide.
PrednisoloneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisone.
ProbenecidThe protein binding of Tolazamide can be decreased when combined with Probenecid.
ProgesteroneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Progesterone.
PropranololPropranolol may increase the hypoglycemic activities of Tolazamide.
QuetiapineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quetiapine.
QuinethazoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quinethazone.
QuinineTolazamide may increase the hypoglycemic activities of Quinine.
RanitidineThe serum concentration of Tolazamide can be increased when it is combined with Ranitidine.
RasagilineRasagiline may increase the hypoglycemic activities of Tolazamide.
RepaglinideTolazamide may increase the hypoglycemic activities of Repaglinide.
RifampicinThe serum concentration of Tolazamide can be decreased when it is combined with Rifampicin.
RisperidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ritonavir.
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Tolazamide.
SafrazineSafrazine may increase the hypoglycemic activities of Tolazamide.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Tolazamide.
SaquinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Tolazamide.
SelegilineSelegiline may increase the hypoglycemic activities of Tolazamide.
SertralineSertraline may increase the hypoglycemic activities of Tolazamide.
SirolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Sirolimus.
SitagliptinSitagliptin may increase the hypoglycemic activities of Tolazamide.
SotalolSotalol may increase the hypoglycemic activities of Tolazamide.
StanozololStanozolol may increase the hypoglycemic activities of Tolazamide.
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Tolazamide.
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Tolazamide.
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Tolazamide.
SulodexideSulodexide may increase the hypoglycemic activities of Tolazamide.
SunitinibTolazamide may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Tacrolimus.
TemsirolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Temsirolimus.
TestosteroneTestosterone may increase the hypoglycemic activities of Tolazamide.
TimololTimolol may increase the hypoglycemic activities of Tolazamide.
TipranavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Tipranavir.
TolbutamideTolazamide may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Tolazamide.
TorasemideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Torasemide.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolazamide.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Tolazamide.
TrazodoneTrazodone may increase the hypoglycemic activities of Tolazamide.
TriamcinoloneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Triamcinolone.
TrichlormethiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Trichlormethiazide.
TriptorelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Triptorelin.
TroglitazoneTroglitazone may increase the hypoglycemic activities of Tolazamide.
VilazodoneVilazodone may increase the hypoglycemic activities of Tolazamide.
VildagliptinVildagliptin may increase the hypoglycemic activities of Tolazamide.
VogliboseVoglibose may increase the hypoglycemic activities of Tolazamide.
VoriconazoleThe serum concentration of Tolazamide can be increased when it is combined with Voriconazole.
VorinostatThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Tolazamide.
WarfarinTolazamide may increase the anticoagulant activities of Warfarin.
ZimelidineZimelidine may increase the hypoglycemic activities of Tolazamide.
ZiprasidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Szabo C, Salzman AL: Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4. [PubMed:8799949 ]
  4. Asano K, Cortes P, Garvin JL, Riser BL, Rodriguez-Barbero A, Szamosfalvi B, Yee J: Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Kidney Int. 1999 Jun;55(6):2289-98. [PubMed:10354277 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23